Cargando…
Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal Cancer
The long-term efficacy of the Epidermal Growth Factor Receptor (EGFR)-targeted antibody cetuximab in advanced colorectal cancer (CRC) patients is limited by the emergence of drug-resistant (persister) cells. Recent studies in other cancer types have shown that cells surviving initial treatment with...
Autores principales: | Lorenzato, Annalisa, Magrì, Alessandro, Matafora, Vittoria, Audrito, Valentina, Arcella, Pamela, Lazzari, Luca, Montone, Monica, Lamba, Simona, Deaglio, Silvia, Siena, Salvatore, Bertotti, Andrea, Trusolino, Livio, Bachi, Angela, Di Nicolantonio, Federica, Bardelli, Alberto, Arena, Sabrina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140052/ https://www.ncbi.nlm.nih.gov/pubmed/32183295 http://dx.doi.org/10.3390/cancers12030685 |
Ejemplares similares
-
Evolving neoantigen profiles in colorectal cancers with DNA repair defects
por: Rospo, Giuseppe, et al.
Publicado: (2019) -
Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies
por: Russo, Mariangela, et al.
Publicado: (2018) -
Colorectal cancer patient-derived organoids and cell lines harboring ATRX and/or DAXX mutations lack Alternative Lengthening of Telomeres (ALT)
por: Falcinelli, Marta, et al.
Publicado: (2023) -
Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
por: Van Emburgh, Beth O., et al.
Publicado: (2016) -
Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers
por: Misale, Sandra, et al.
Publicado: (2015)